or
forgot password

DNA Chip Based Prognosis of Lung Cancer


N/A
18 Years
75 Years
Open (Enrolling)
Both
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

DNA Chip Based Prognosis of Lung Cancer


Inclusion Criteria:



1. A histological diagnosis of primary NSCLC stage Ia

2. Surgical removal of the tumor

3. Age between 18 and 75 years

4. Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC
stage Ib-IV after surgery.

2. Adjuvant treatment with chemotherapy.

3. Prior history of cancer in the past 5 years or breast cancer at any time.

4. Life expectancy less than 3 years in the opinion of the investigator due to
concurrent illnesses.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Steen Knudsen, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Medical Prognosis Institute (MPI)

Authority:

United States: Institutional Review Board

Study ID:

MPI-1001

NCT ID:

NCT00973427

Start Date:

June 2008

Completion Date:

May 2012

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • NSCLC
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

University of Alabama Birmingham, Alabama  
Roswell Park Cancer Institute Buffalo, New York  14263